- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2824EUR$3,250USD£2,462GBP
- Report
- October 2022
- 100 Pages
Global
From €2172EUR$2,500USD£1,894GBP
- Report
- September 2022
- 288 Pages
Global
From €8255EUR$9,500USD£7,196GBP
- Report
- September 2022
- 239 Pages
Global
From €6517EUR$7,500USD£5,681GBP
- Report
- April 2020
- 80 Pages
Global
From €3432EUR$3,950USD£2,992GBP
- Report
- December 2024
- 87 Pages
Spain
From €3041EUR$3,500USD£2,651GBP
- Report
- July 2024
- 80 Pages
Japan
From €3041EUR$3,500USD£2,651GBP
- Report
- November 2023
- 78 Pages
France
From €3041EUR$3,500USD£2,651GBP
- Report
- November 2023
- 78 Pages
Germany
From €3041EUR$3,500USD£2,651GBP
- Report
- November 2023
- 83 Pages
Germany
From €3041EUR$3,500USD£2,651GBP
- Report
- January 2025
- 140 Pages
Asia Pacific
From €3476EUR$4,000USD£3,030GBP
- Report
- May 2024
- 182 Pages
Global
From €3910EUR$4,500USD£3,409GBP
- Report
- October 2023
- 73 Pages
Canada
From €3041EUR$3,500USD£2,651GBP
- Report
- May 2024
- 298 Pages
Global
From €6908EUR$7,950USD£6,022GBP
- Report
- May 2023
- 200 Pages
Global
From €6517EUR$7,500USD£5,681GBP
- Report
- May 2023
- 220 Pages
Global
From €2172EUR$2,500USD£1,894GBP
- Report
- May 2023
- 450 Pages
Global
From €4345EUR$5,000USD£3,788GBP
- Report
- February 2021
- 50 Pages
Global
From €2824EUR$3,250USD£2,462GBP
- Report
- December 2024
- 175 Pages
Global
From €4345EUR$5,000USD£3,788GBP
- Report
- June 2021
Global
From €3476EUR$4,000USD£3,030GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more